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Background: While substance abuse among psychiatric patients is a widely known problem in clinical practice, there is no local study 
about prevalence and co-occurrence of substance abuse in north of Iran.
Objectives: The present study was designed to determine the frequency of smoking, alcohol, opioid and cannabinoid substances, and 
prescription medicines abuse or dependence among Psychiatric Inpatients.
Patients and Methods: A cross-sectional 2-year case register study was conducted on all (n = 492) psychiatric inpatients of Zare Psychiatric 
Hospital in Sari located in north of Iran. The data were obtained by using a standardized and validated questionnaire that contained 
demographic information along with information on co-morbid psychiatric problems and alcohol, cannabinoids, opioids, and cigarette 
usage. 
Results: The mean (± SD) age of samples was 39.9 (± 11.9) years and male:female ratio was 3.6. Opium with or without using other illicit 
substances was the most frequently abused substance (67%). Significant association were found between illicit substance abuse and 
demographic variables of male gender, a low level of literacy, living in the urban area, unemployment, cigarette smoking, and young age. 
There were statistically significant association between schizophrenia and substance abuse (P < 0.001).
Conclusion: High prevalence of dual diagnosis warrants attention to the management of substance misuse while treating mental 
disorders, and should be incorporated in the holistic treatment plan of psychiatric inpatients. 
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1. Background
Substance abuse among psychiatric patients is a widely 
known problem. Although the precise extent and detail 
of this phenomenon is unclear (1), in recent decades vast 
majority of studies reported a high rate of co-occurrence 
of substance use disorders with psychiatric disorders 
(2). Numerous epidemiological surveys have found high 
rates of substance misuse among psychiatric patients. 
This co-occurrence, which is also called dual diagnosis, 
contributes to poorer motivation and treatment compli-
ance as well as outcomes (3).
Dual diagnosis is the term used to describe patients 
with both severe mental illness (mainly psychotic dis-
orders) and problematic drug and or alcohol use. The 
term originated from the United States in the 1980s and 
has been adopted in the United Kingdom and other 
countries more recently. The nature of the relationship 
between the two conditions is complex and sometimes 
controversial (4). 
A primary psychiatric illness may trigger or lead to 
substance misuse and this phenomenon may worsen or 
change the outcome of a psychiatric illness. On the other 
hand, substance misuse and or withdrawal may result in 
psychiatric symptoms or illness. It may also act as a trig-
ger or precipitating factor in those predisposed to men-
tal illness (5).
Research studies have indicated that at least one-half 
of the patients in psychiatric or substance misuse treat-
ment centers have been diagnosed with co-morbid psy-
chiatric and substance use disorders (6).
Many studies have shown high prevalence of alcohol 
abuse among patients with depression and some have 
found increasing opiates use in schizophrenia (7). This is 
clinically important as this co-morbidity has a negative 
impact on the treatment of both conditions (3). While 
many different epidemiological factors contribute to this 
phenomenon, inconsistent results have been observed in 
different studies (8). As a result, the findings could not be 
generalized to other societies and even to a certain disease.
Iran because of its vicinity to Afghanistan, the biggest 
world supply of opium, has a high exposure rate to opi-
um and its derivatives and accordingly there are more 
reports of opiate dependency (9).
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2. Objectives
Considering the importance of substance use among 
psychiatric patients and its effect on the recovery process 
emphasized in numerous studies, the present study was 
designed to determine (a) the frequency of smoking, al-
cohol, opioid and cannabinoid substances, and prescrip-
tion medicines abuse or dependence, and (b) types of 
psychiatric disorders in patients with substance abuse.
3. Patients and Methods
A cross-sectional 2-year case register study was con-
ducted on all adult (> 18 years) psychiatric inpatients (n 
= 492) of Zare Psychiatric Hospital in Sari, Mazandaran, 
a northern province of Iran at the southern border of 
Caspian Sea. The patients were evaluated by conducting a 
structured interview and completing a questionnaire to 
record demographic, and disease-related information. It 
also contained detailed information on the type and pat-
tern of alcohol, smoking, and two most prevalent drugs 
of abuse in Iran (opioid and cannabinoid substances). To 
complete the assessment process collateral information 
were also obtained from family members and patients’ 
hospital case files.
The questionnaire consisted of 27 items collecting data 
on the demographic characteristics (8 questions), psychi-
atric co-morbidities (5 questions), and substance/drug 
abuse/dependence (14 questions). The questionnaire had 
been designed by the researchers and validated by peer 
review and a pilot study (Cronbach α = 0.92).
The psychiatric diseases were diagnosed and confirmed 
by using clinical information according to the DSM-IV-TR 
criteria (10). Urine test was performed to detect opioid 
and cannabinoid substances recently used using the Sure 
Step TM kits (Applied Biotech Inc.). Statistical Package for 
the Social Sciences (SPSS - v14) free version was used to 
analyze the data by using descriptive statistics and mea-
sures of association (Pearson and chi-square).
4. Results
The mean ± SD age of samples was 39.9 ± 11.9 years and 
male:female ratio was 3.6 (385 men vs. 107 women). 
More than 60% (n = 307) of the patients were living in 
the city. Approximately 60% (n = 294) of the patients were 
unemployed, and 95.7% (n = 471) had high school diploma 
or a lower educational degree. Over half of the patients (n 
= 253) were married and 8.9% (n = 44) were divorced. The 
most frequent observed psychiatric disorder was schizo-
phrenia (36.6%) (Table 1).
The mean ± SD disease duration was 104 ± 11.3 months, 
(95% CI, 103.02-104.98) and mean ± SD hospitalization rate 
was 2.5 ± 0.4 times (95% CI, 2.46-2.53).
According to urine test, the rate of current substance 
abuse or dependence in all patients was about 52.2%. In 
addition, there were 238 (46.6%) current smoker patients 
in the sample. The mean age onset of smoking was 20.5 
(± 3.4) years. Lifetime abuse or dependence rate in all psy-
chiatric inpatients has been shown in Table 2. Prescrip-
tion medicines abuse or dependence prevalence was 7.5% 
(n = 37). Benzodiazepines were the most misused group 
(in all 37 patients) either alone or in combination with 
other medicines. Antidepressants took the second place 
with 31% and anticholinergic agents with 20% took the 
third place.
According to urine test, current opioid and cannabi-
noid substances or prescription medicines abuse or de-
pendence was reported in 130 patients (26.4%). According 
to the questionnaire results, prevalence of lifetime abuse 
or dependence among hospitalized psychiatric patients 
was more than half (n = 257, 52.2%) with nearly 158 (32.1%) 
of these patients having the history of at least one sub-
stance abuse (Table 2).
Opium with or without other substances was the most 
frequent substance abused in 67% of cases (Table 3). The 
mean ± SD age of onset for substances use was 22.2 ± 2.8, 
(95% CI, 22.16-22.23) and mean ± SD rate for abstinence was 
2 ± 0.4. Family pressure was reported as the main reason 
for quitting substance misuse.
Schizophrenia and mood disorders were the two most 
common psychiatric disorders in substance abuser or de-
pendent inpatients, but schizophrenia had a statistically 
significant association with substance misuse or depen-
dence (P < 0.001) (Table 4).
We also found a significant association of opioid and 
cannabinoid substances abuse or dependence with many 
demographic factors like male gender, lower education-
al achievement, living in the city, unemployment, and 
younger age (Table 5).
Finally, we found strong association between current 
smoking and opioid-cannabinoid substances abuse or 
dependence (P < 0.001, χ2 = 32.23). We also found that 
substance abuse or dependence started approximately 2 
years after patients began smoking.
Table 1. Frequency of Psychiatric Disorders in all 492 Inpa-
tients a, b
Variables Female Male Total
Disorders
Schizophrenia 34 (6.9) 146 (29.7) 180 (36.6)
Bipolar disorder 39 (7.9) 90 (18.3) 129 (26.2)
MDD with or without PF 20 (4.1) 40 (8.1)  60 (12.2)
Substance induced mood 
disorders
1 (0.2) 38 (7.7) 39 (7.9)
Other psychotic disorders 9 (1.8) 22 (4.5) 31 (6.3)
Personality disorders 1 (0.2) 15 (3.0) 16 (3.3)
Other psychiatric disorders 3 (0.6) 34 (6.9) 37 (7.5)
a  Abbreviations: MDD, major depressive disorder; PF, psychotic features.
b  Data are presented as No. (%).
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Table 2. Lifetime Abuse/Dependence Rate in all Psychiatric Inpa-
tients a, b
Substance/medicines of abuse/dependence Values
Alcohol 45 (9.1)
Prescription Medicines 37 (7.5)
Opioid and Cannabinoid Substances 158 (32.1)
Smoking 238 (48.4)
No abuse/dependence 235 (47.8)
a  Due to occurrence of more than one substance/drug abuse/
dependence in many patients, figures add up to more than the total 
sample.
b  Data are presented as No. (%).
Table 3. Lifetime Prevalence of Substance Abuse/Dependence by 
Sex a
Substance Opium Hashish Heroin Grass
Gender
Female 3 (2.2) 1 (0.7) 0 (0) 1 (0.7)
Male 84 (64.7) 60 (46.2) 29 (22.3) 18 (13.7)
Total 87 (67) 61 (47) 29 (22.3) 19 (14.5)
a  Data are presented as No. (%).
Table 4. Association of Psychiatric Disorders With Current Sub-
stance Abuser/Dependency a
Abuse Urine Test P Value χ2
Positive Total
Disorders
Schizophrenia 34 180 0.000 17.71
Bipolar disorder 34 129 0.257 1.28
MDD with or without PF† 12 60 0.195 0.375
Other psychotic disorders 10 31 0.936 5.28
Personality disorders 9 16 0.171 0.72
Other psychiatric disorders 10 37 0.005 6.72
a  Abbreviations: MDD, major depressive disorder; PF, psychotic features.
Table 5. Association Between Demographic Characteristics and 
Current Substance Abuse
Demographic variables P Value χ2
Male gender 0.000 29.21
Lower educational level 0.001 9.84
Unemployment 0.025 7.78
Younger age 0.000 22.65
Living in the city 0.004 16.42
5. Discussion 
Substance abuse has been reported in association with 
various medical conditions. Research has shown a con-
siderable tobacco and opium dependence with the rate 
of 44.2% and 5.8% for heart diseases and 17.9% and 7.1% for 
pulmonary diseases, respectively (11). This phenomenon 
has been reported in many other medical diseases, in-
cluding rheumatologic diseases (12) and hemophilia (13).
In our study, the rate of substance abuse in the psychiat-
ric inpatients was higher than the rate of this co-morbid-
ity that has been reported in the literature in association 
with any other medical condition. This may be due to 
the nature of psychiatric problems and therefore needs 
more attention during the treatment process (14).
Although we found an association of substance depen-
dence with two groups of psychiatric disorders, only 
in one of these, i.e. schizophrenia, the association was 
statistically significant and in the second group (other 
psychiatric disorders, containing a large number of non-
specific psychiatric disorders), it was not.
In our study the smoking rate was approximately three 
times higher than what has been reported in the general 
population (15). Smoking in psychiatric patients increas-
es the activity of P450 system in the liver and CYP1A2 en-
zymes, thus decreases the blood concentration of many 
antipsychotic drugs and their side effects, which might 
be rewarding for the patients (16). Our study also found 
a strong relationship between smoking and substance 
abuse event prior to the onset of psychiatric disorders. 
There are many differences in the type of substance 
abuse or dependence and specific psychiatric disorders 
and their association in the literature. Studies have 
shown a different pattern of substance abuse or depen-
dence in Iran compared to the rest of the world. These 
differences are partly cultural and partly due to the 
availability of substances in this part of the world. For 
example, raw opium dependence is quite common be-
cause Iran is a neighbor to Afghanistan which is the main 
producer of this substance in the world (17). Opioids are 
the primary drugs of abuse in Iran. Two different forms 
of opioid abuse afflict Iran; heroin injection and opium 
smoking and ingestion (18). Indigenous raw opium ac-
counts for 69% to 94.6% of total opioid use in this country 
(16). Cannabinoid substances are the second prevalent 
drugs of abuse in Iran (19). 
There are a number of reasons why patients with dual 
diagnosis do not receive the necessary care. These rea-
sons include lack of treatment access, high cost of treat-
ment, stigmatization, treating only mental illness or sub-
stance use disorders in separation, as well as a medical 
care system that do not put enough emphasis on the rec-
ognition or treatment of a co-morbid substance misuse 
and also a medical education system that dedicate very 
little training or teaching time to this significant area of 
clinical practice (7). 
The results of our study revealed a high prevalence of 
co-morbid substance misuse in psychiatric inpatients, 
which has a significant impact on the management of 
both conditions. In this respect, we recommend that the 
protocol for the management of psychiatric illnesses in 
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psychiatric hospitals be revised so that the early recogni-
tion and management of co-morbid substance misuse 
are more emphasized.
In addition, a strong association of smoking and sub-
stance misuse has been noted in our study. This associa-
tion with high rate of substance misuse warrants further 
studies on how public education about harmful effect of 
cigarette smoking can help reduce the overall rate of sub-
stance dependency in the general population.
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